Personalized pharmacotherapy for Type 2 diabetes mellitus

被引：9

作者：

Sathananthan, Airani ^{[1
]}

Vella, Adrian ^{[1
]}

机构：

[1] Mayo Clin, Div Endocrinol Diabet & Metab, Dept Med, Rochester, MN 55905 USA

来源：

PERSONALIZED MEDICINE | 2009年 / 6卷 / 04期

关键词：

OCT; 1; pharmacogenetics; sulfonylureas; TCF7L2; Type 2 diabetes mellitus; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; INSULIN-SECRETION; SECONDARY FAILURE; INCREASED RISK; TCF7L2; GENE; VARIANT; SULFONYLUREA; THERAPY; POLYMORPHISMS; PIOGLITAZONE;

D O I：

10.2217/PME.09.3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.

引用

页码：417 / 422

页数：6

共 50 条

[21] Cardiac Computed Tomography for Personalized Management of Patients With Type 2 Diabetes Mellitus
Cardoso, Rhanderson
Dudum, Ramzi
Ferraro, Richard A.
Bittencourt, Marcio
Blankstein, Ron
Blaha, Michael J.
Nasir, Khurram
Rajagopalan, Sanjay
Michos, Erin D.
Blumenthal, Roger S.
Cainzos-Achirica, Miguel
CIRCULATION-CARDIOVASCULAR IMAGING, 2020, 13 (09)
[22] Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach
Cornell, S.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (03) : 254 - 259
[23] Pharmacotherapy of type 2 diabetes: An update
Upadhyay, Jagriti
Polyzos, Stergios A.
Perakakis, Nikolaos
Thakkar, Bindiya
Paschou, Stavroula A.
Katsiki, Niki
Underwood, Patricia
Park, Kyung-Hee
Seufert, Jochen
Kang, Eun Seok
Sternthal, Elliot
Karagiannis, Asterios
Mantzoros, Christos S.
METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 78 : 13 - 42
[24] Early pharmacotherapy for type 2 diabetes
Westphal K.
MMW - Fortschritte der Medizin, 2023, 165 (19) : 18 - 18
[25] Pharmacotherapy Of Type 2 Diabetes - The Future
Abhay, A. P.
Ravichand, D. M.
Seshayamma, V
chandran, Satish P.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2006, 4 (03) : 151 - 166
[26] The economics of pharmacotherapy for diabetes mellitus
Costa, B
Arroyo, J
Sabate, A
PHARMACOECONOMICS, 1997, 11 (02) : 139 - 158
[27] The Economics of Pharmacotherapy for Diabetes Mellitus
Bernardo Costa
Jaume Arroyo
Angels Sabaté
PharmacoEconomics, 1997, 11 : 139 - 158
[28] Pharmacotherapy for patients with diabetes mellitus
Moon, Joon Ho
Lim, Soo
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2020, 63 (12): : 766 - 775
[29] Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 2
Washburn, William N.
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (07) : 1785 - 1794
[30] Impact of CV Mortality Risk Perception on Patient Preferences for Type 2 Diabetes Mellitus Pharmacotherapy
Lam, Amanda
Ozdemir, Semra
Verghese, Naina
Baid, Drishti
Ganguly, Sonali
Lee, Phong Ching
Lim, Adoree Y. Y.
Zhu, Ling
Finkelstein, Eric
Goh, Su-Yen
CIRCULATION, 2019, 140

← 1 2 3 4 5 →